Active Clinical Trials

We currently have the following trials open:

HIC # 1107008825

Principal Investigator: Anees Chagpar, MD

A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients


HIC # 0705002671

Principal Investigator: Maysa Abu-Khalaf, MD

Q3 Week Carbo with Weekly Abraxane and Avastin in Resectable and Nonresectable HER2 Negative Breast Cancer


HIC # 0705002672

Principal Investigator: Maysa Abu-Khalaf, MD

Q3 Week Carbo with Weekly Abrax/trastuzumab in Resectable and Nonresectable HER2+ Breast Cancer


HIC # 1102008055

Principal Investigator: Tara Sanft, MD

Delivery of Survivorship Care Plans


HIC #1104008282

Principal Investigator: Lyndsay Harris, MD

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score of 25 or Less


HIC # 1104008407

Principal Investigator: Erin Hofstatter, MD

A Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Postoperative Adjuvant Therapy in Node Positive or High-Risk Node Negative Breast Cancer


HIC # 0909005727 (CALBG 40502)

Principal Investigator: Lyndsay Harris, MD

A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-line Therapy or Locally Recurrent or Metastatic Breast Cancer


HIC # 0803003591

Principal Investigator: Maysa Abu-Khalaf, MD

A Dose-escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) in Combination with Capecitabine (xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer


HIC # 0909005747

Principal Investigator: Maysa Abu-Khalaf, MD

A Phase I/Ib, Multicenter, Open-Label Study of BEZ235, Administered Orally on Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies including Patients with Advanced Breast Cancer


HIC # 1103008138

Principal Investigator: Lyndsay Harris, MD

A Randomized Phase II Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment



HIC # 0909005728 (CALGB 40503)

Principal Investigator: Lyndsay Harris, MD

Endocrine Therapy in Combination with Anti-VEGF Therapy: A Randomized Double-blind, Placebo-controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab for Women with Hormone Receptor Positive Advanced Breast Cancer


HIC # 1102007970

Principal Investigator: Erin Hofstatter, MD

A Phase II Prospective Trial Correlating PFS with CYP2D6 Activity in Patients with Metastatic Breast Cancer

RTOG 0413

Principal Investigator: Joanne Weidhaas, MD, PhD     

RCT of APBI vs. Whole Breast Irradiation

HOPE Study

Principal Investigator: Melinda Irwin, PhD

Exercise Trial for Women Taking AIs Evaluating if Exercise Improves Side Effects of AIs

LEAN Study

Principal Investigator: Melinda Irwin, PhD

Weight-Loss Trial for Breast Cancer Survivors with BMI >=25 with Diet and Exercise

Yale FIT

Principal Investigator: Tish Knobf, PhD

RCT of Aerobic Exercise vs. Home-based Physical Activity


Heart Strong

Principal Investigator: Tish Knobf, PhD

Cardiac Risk Assessment in Women who will Receive Anthracycline and/or Herceptin Therapy


Subclinical Lymphedema, Psychosocial and Functional Outcomes after Lymph Node Surgery

Principal Investigator: Anees Chagpar, MD


A Phase I Multiple Dwell Mammosite Trial

Principal Investigator: Joanne Weidhaas, MD, PhD